Bristol-Myers Squibb Management
Management criteria checks 3/4
Bristol-Myers Squibb's CEO is Chris Boerner, appointed in Nov 2023, has a tenure of 1.08 years. total yearly compensation is $8.46M, comprised of 14.9% salary and 85.1% bonuses, including company stock and options. directly owns 0.005% of the company’s shares, worth $5.78M. The average tenure of the management team and the board of directors is 2.9 years and 4.3 years respectively.
Key information
Chris Boerner
Chief executive officer
US$8.5m
Total compensation
| CEO salary percentage | 14.9% |
| CEO tenure | 1.1yrs |
| CEO ownership | 0.005% |
| Management average tenure | 2.9yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued
Dec 20Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year
Dec 15
Revenues Not Telling The Story For Bristol-Myers Squibb Company (NYSE:BMY)
Nov 275 Reasons Bristol-Myers Squibb Looks Good Now (Rating Upgrade)
Nov 25Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren
Oct 28Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon
Oct 06Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Sep 27Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows
Sep 06Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues
Aug 15Bristol-Myers Squibb: A Potential Comeback In Healthcare
Aug 06Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point
Jul 27Bristol Myers Squibb: The More It Drops, The More I Buy
Jul 16Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?
Jun 13Bristol Myers: Quality Fundamentals Suppressed By Interest Rates
Jun 09Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss
Jun 03Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity
May 23Bristol-Myers Squibb: A Lost Decade?
May 03Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S
Apr 29Is Bristol Myers Squibb A Buy At These Bottom Levels?
Apr 22Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
Apr 12Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)
Apr 02Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60
Mar 21Bristol-Myers Squibb Is Not A Buy For Me
Mar 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$7b |
| Jun 30 2024 | n/a | n/a | -US$7b |
| Mar 31 2024 | n/a | n/a | -US$6b |
| Dec 31 2023 | US$8m | US$1m | US$8b |
| Sep 30 2023 | n/a | n/a | US$8b |
| Jun 30 2023 | n/a | n/a | US$8b |
| Mar 31 2023 | n/a | n/a | US$7b |
| Dec 31 2022 | US$7m | US$1m | US$6b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jun 30 2022 | n/a | n/a | US$7b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$7m | US$1m | US$7b |
| Sep 30 2021 | n/a | n/a | -US$5b |
| Jun 30 2021 | n/a | n/a | -US$5b |
| Mar 31 2021 | n/a | n/a | -US$6b |
| Dec 31 2020 | US$6m | US$953k | -US$9b |
| Sep 30 2020 | n/a | n/a | -US$44m |
| Jun 30 2020 | n/a | n/a | -US$563m |
| Mar 31 2020 | n/a | n/a | US$954m |
| Dec 31 2019 | US$6m | US$891k | US$3b |
Compensation vs Market: Chris's total compensation ($USD8.46M) is below average for companies of similar size in the US market ($USD12.88M).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
CEO
Chris Boerner (53 yo)
1.1yrs
Tenure
US$8,461,833
Compensation
Dr. Christopher S. Boerner, also known as Chris, Ph.D. served as Chief Operating Officer at Bristol-Myers Squibb Company since April 26, 2023 to 2023 and served as its Executive Vice President since April...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 1.1yrs | US$8.46m | 0.0051% $ 5.8m | |
| Executive VP & CFO | 5.1yrs | US$7.17m | 0.0096% $ 11.0m | |
| Executive VP & General Counsel | 17.8yrs | US$5.92m | 0.022% $ 25.2m | |
| Executive VP | 5.5yrs | US$6.23m | 0.0031% $ 3.5m | |
| Executive VP and Chief Digital & Technology Officer | 2.9yrs | no data | 0.00026% $ 296.9k | |
| VP & Head of Investor Relations | no data | no data | no data | |
| Chief Compliance & Ethics Officer | 1.2yrs | no data | no data | |
| Executive Vice President & Chief Human Resources Officer | less than a year | no data | 0.00013% $ 148.4k | |
| Head of Medical Affairs | no data | no data | no data | |
| Executive VP | no data | no data | 0.00080% $ 913.5k | |
| Senior Vice President of Major Markets | no data | no data | no data | |
| Executive Vice President of Global Product Development & Supply | 2.9yrs | no data | 0.00031% $ 354.0k |
2.9yrs
Average Tenure
54.5yo
Average Age
Experienced Management: BMY's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 1.9yrs | US$8.46m | 0.0051% $ 5.8m | |
| Independent Director | 4.3yrs | US$375.00k | 0% $ 0 | |
| Independent Director | 5.1yrs | US$365.00k | 0% $ 0 | |
| Independent Director | 8.7yrs | US$359.68k | 0% $ 0 | |
| Independent Director | 2.5yrs | US$329.97k | 0% $ 0 | |
| Lead Independent Director | 7.8yrs | US$425.00k | 0.0018% $ 2.0m | |
| Independent Director | 4.3yrs | US$365.00k | 0% $ 0 | |
| Independent Director | 5.1yrs | US$371.68k | 0.00067% $ 765.0k | |
| Independent director | less than a year | no data | 0.000050% $ 57.1k | |
| Independent Director | 6.9yrs | US$344.74k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$335.00k | 0% $ 0 |
4.3yrs
Average Tenure
63yo
Average Age
Experienced Board: BMY's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 04:48 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bristol-Myers Squibb Company is covered by 51 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Charles Butler | Barclays |